Takeda (TAK) has identified both rare diseases and gastrointestinal diseases (or GI) as key areas of interest and R&D focus. On Thursday morning, Takeda put even more money on the table, signing a partnership agreement with Arrowhead Pharmaceuticals (ARWR) for its ARO-AAT RNA interference (or RNAi) drug for alpha-1 antitrypsin-associated liver disease (or AATLD).
With Arrowhead having a multiyear head start, and recently producing very encouraging data from a small Phase II cohort, this is a promising deal for Takeda. Given the mechanisms of action, RNAi drugs should have relatively lower late-stage failure rates, and the market opportunity in AATLD could be in the several billions of dollars. While Takeda’s size does limit the materiality of this deal to a point, an upfront investment of $300M for the chance at a multibillion-dollar drug is a deal worth doing, and for Arrowhead this yet another Big Pharma partnership to help validate a striking clinical comeback with a new delivery technology.
Read more here:
Takeda Broadens Its Rare Disease Portfolio By Partnering With Arrowhead
No comments:
Post a Comment